Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)
Sponsored by The University of Texas Health Science Center, Houston
About this study
The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients.
Where this study is enrolling
- I'm interested
The University of Texas Health Science Center at Houston
Houston, Texas
Who can participate
Inclusion criteria
- ✓Individuals diagnosed with SMDS with confirmed ACTA2 mutation disrupting arginine 179
- ✓Parental/guardian permission (informed consent) and, if appropriate, child assent.
Exclusion criteria
- ✕Individuals who have undergone surgery to replace aneurysmal or dissected ascending and root aortic tissue with a graft.
- ✕Additional medical conditions that impair the patient's ability to participate in the study.
- ✕Known allergy or sensitivity to niacin or nicotinamide riboside.
- ✕Prior consumption of niacin or nicotinamide riboside supplement within the prior eight weeks.
- ✕Failure to provide informed consent.
- ✕Concurrent participation in another intervention trial.
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.